Bio/Pharmaceutical Outsourcing Report, August 2026

All the vital news, analysis, and commentary curated by our industry experts.

$2950

Buy Report

Published: September 18, 2026 Report Code: GDPB092-ST

Report Overview
Key Players
Table of Contents
Table
Figures

The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.

Scope

This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from GlobalData's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for:

– CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.

– Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.

– Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.

Reasons to Buy

Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.

Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.

Learn about the past quarter’s M&A and financing deals in the manufacturing space.

Identify the latest contract service agreements.

Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.

Stay ahead of disruption with updates on supply chain obstacles and new regulations.

Aenova Holding GmbH
AGC Biologics Inc
Alcami Corp
Aldevron LLC
Altasciences Co Inc
Anapharm Bioanalytics
Apitoria Pharma Pvt Ltd
Bachem Holding AG
Bayer Plc
Besins Healthcare SA
Biocon
BriaCell Therapeutics Corp
Bristol Myers Squibb (BMS)
Cambrex Corp
Cellares Corp
Cellipont Bioservices
Chemo Holding SL
Chimeric Therapeutics Ltd
Civica Inc
Corden Pharma International GmbH
Dash Bio Inc
Delpharm SAS
ElevateBio LLC
Eli Lilly and Co
Emergent BioSolutions Inc
EuroAPI Italy Srl
EuroAPI SA
Fujifilm Diosynth Biotechnologies UK Ltd
Fujifilm Diosynth Biotechnologies USA Inc
Genethon SA
Genezen Laboratories Inc
Hovione
Huvepharma AD
Imunon Inc
Incyte Biosciences UK Ltd
Intertek Group Plc
Janssen-Cilag International NV
KBI Biopharma Inc
Kincell Bio LLC
Kirin Holdings Co Ltd
Landmark Bio PBLLC
LTS Lohmann Therapie-Systeme AG
Made Scientific
Merck KGaA
Moderna Inc
MoonLake Immunotherapeutics
National Resilience Inc
Nikon CeLL Innovation Co Ltd
Novartis AG
Novartis UK Ltd
NurExone Biologic Inc
Occam Systems
Oxford BioMedica Plc
Patheon NV
Piramal Pharma Solutions Inc
Pluristyx Inc
PolyPeptide SA
Regeneron
Richter-Helm BioLogics GmbH & Co KG
ROVI Pharma Industrial Services SAU
Rhythm Pharmaceuticals Inc
Samsung Biologics Co Ltd
Sanofi
Santen UK Ltd
SEQENS
Sharp Packaging Services LLC
Siegfried Holding AG
Siemens AG
Simtra US LLC
Syngene
Taysha Gene Therapies Inc
Thea Group
Unither Pharmaceuticals SAS
Vetter Pharma-Fertigung GmbH & Co KG
WuXi AppTec Co Ltd
WuXi Biologics (Hong Kong) Ltd
Xencor Inc
Zenas BioPharma Inc
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Raybow Pharmaceutical Co Ltd

Table of Contents

1 Industry Trends

1.1 Create a plan and then add a backup: the impact of US generic drug tariffs

1.2 BMS Texas investment advances pharma’s modular manufacturing agenda

1.3 Novo"s Bloomington site faces ongoing regulatory issues

1.4 Looking beyond short-term turmoil, Syngene is investing for the future

2 Industry Analysis

2.1 Contract service agreements

2.2 Contract manufacturing – opportunities and threats

2.3 Quarterly mergers, acquisitions, and financing – Q3 2026

3 Value Chain

3.1 API chemical

3.2 API biologics – cell, gene, vaccine, and virus

3.3 API biologics – protein and peptide

3.4 Commercial dose manufacturing and packaging

3.5 Analytical services

4 About GlobalData

5 About the Authors

6 Contact Us

Table

Table 1: Contract service agreements

Table 2: Contract manufacturing: opportunities and threats – potentially positive

Table 3: Contract manufacturing: opportunities and threats – potentially negative

Table 4: Mergers, acquisitions, and financing – Q3 2026

Figures

Figure 1: Contract service agreements by deal geography, by volume

Figure 2: Deals by deal geography, by volume – mergers, acquisitions, and financing

Figure 3: The contract manufacturing value chain

Bio/Pharmaceutical Outsourcing Report, August 2026 standard reports

Currency USD

Single User

$2,950

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Contract Manufacturers reports

Pharmaceuticals

New

CRO Activity and Intel Report Q3 2026

Pharmaceuticals

New

Acne Vulgaris: Market View, Current and Future Competitive Landscape

Pharmaceuticals

New

M&A in the Contract Manufacturing Industry: Implications and Outlook -…

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Bio/Pharmaceutical Outsourcing Report, August 2026 in real time.

Access a live Bio/Pharmaceutical Outsourcing Report, August 2026 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Bio/Pharmaceutical Outsourcing Report, August 2026

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports